Pharmaceutical Technology\'s In the Lab eNewsletter-10-02-2019

Changes in CCIT testing have followed the evolution of regulatory guidance, and this article examines different possible CCIT strategy approaches.

Mass spectrometry should be utilized effectively to optimize biosimilar analysis, which can reduce development time and cost.

The cytometry system is available with up to five lasers to analyze up to 40 markers in one sample.

The company continues to expand globally through the completion of the Goldman Sachs 10,000 Small Businesses program and the hiring of Dr. Jas Douville, the company’s new head of business development for North America.

The newly added service will focus on clinical analytics service and clinical operations capabilities.

The new feature enables control of bead formation and rapid production of particles with different sizes, shapes, and morphologies.

BioIVT has announced that it has joined the Medicines Discovery Catapult’s Discovery Services Platform, which is aimed at supporting drug discovery within the United Kingdom.

PPD is expanding its bioanalytical lab in Richmond, VA, to enhance its immunochemistry, biomarker, and chromatography services.

A new educational platform by Quality Executive Partners offers on-demand digital courses with technical content, virtual reality, and real-time coaching with an initial focus on sterile product manufacturing and microbiology.

Cellink’s BIO X6, a six-printhead bioprinting platform, offers the capability to combine more materials, cells, and tools to enhance research applications across the bioprinting field.

Cell DIVE is a new cell imaging technology from GE Healthcare that allows for more precise biomarker analysis.

The new microscope gives fast, deep, and clear images for live observation over long periods and allows scientists to study a larger range of applications.

The organization will utilize the cancer center’s Research for Biologics and Immunotherapy Translation platform for the development of therapeutic monoclonal antibodies against a novel immune checkpoint target.